Meeting
2014 ASCO Annual Meeting
Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.
Authors
LI Liu
GlaxoSmithKline, Oncology, Collegeville, PA
LI Liu , Hong Shi , Maureen R Bleam , Vivian Zhang , Jun Zou , Junping Jing , Kurtis E. Bachman , Monica Motwani , Keith W. Orford , Axel Hoos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3513)
DOI
10.1200/jco.2014.32.15_suppl.3513
Abstract #
3513
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Antitumor activity of panRAF inhibition in BRAF V600E metastatic colorectal cancer.
First Author: Alex Sorokin
Poster
2015 Gastrointestinal Cancers Symposium
Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d’Hebron Institute of Oncology phase I program cohort.
First Author: Enrique Sanz-Garcia
Poster
2012 Gastrointestinal Cancers Symposium
Efficacy of vemurafenib (V) a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.
First Author: Brian Higgins
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC).
First Author: Samuel J Klempner